About Thioredoxin reductase 2, mitochondrial
Thioredoxin reductase 2, mitochondrial (TXNRD2) is a protein
from Homo sapiens identified by UniProt accession
Q9NNW7, 524 residues long.
MolForge cross-references it against 0 known binders and
143 disease associations.
Target properties
| Protein name | Thioredoxin reductase 2, mitochondrial |
| UniProt accession | Q9NNW7 |
| Gene | TXNRD2 |
| Organism | Homo sapiens |
| Length | 524 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (143)
Diseases linked to this target (Open Targets).
- response to tramadol · score 0.50
- familial glucocorticoid deficiency · score 0.47
- familial isolated dilated cardiomyopathy · score 0.37
- neurofibrillary tangles measurement · score 0.23
- intraocular pressure measurement · score 0.22
- open-angle glaucoma · score 0.21
- dilated cardiomyopathy · score 0.21
- Abnormality of the cardiovascular system · score 0.19
- breast adenocarcinoma · score 0.18
- familial hypertrophic cardiomyopathy · score 0.18
Amino-acid sequence (524 residues)
MAAMAVALRG LGGRFRWRTQ AVAGGVRGAA RGAAAGQRDY DLLVVGGGSG GLACAKEAAQ LGRKVAVVDY VEPSPQGTRW GLGGTCVNVG CIPKKLMHQA ALLGGLIQDA PNYGWEVAQP VPHDWRKMAE AVQNHVKSLN WGHRVQLQDR KVKYFNIKAS FVDEHTVCGV AKGGKEILLS ADHIIIATGG RPRYPTHIEG ALEYGITSDD IFWLKESPGK TLVVGASYVA LECAGFLTGI GLDTTIMMRS IPLRGFDQQM SSMVIEHMAS HGTRFLRGCA PSRVRRLPDG QLQVTWEDST TGKEDTGTFD TVLWAIGRVP DTRSLNLEKA GVDTSPDTQK ILVDSREATS VPHIYAIGDV VEGRPELTPI AIMAGRLLVQ RLFGGSSDLM DYDNVPTTVF TPLEYGCVGL SEEEAVARHG QEHVEVYHAH YKPLEFTVAG RDASQCYVKM VCLREPPQLV LGLHFLGPNA GEVTQGFALG IKCGASYAQV MRTVGIHPTC SEEVVKLRIS KRSGLDPTVT GCUG
Explore Thioredoxin reductase 2, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets